Page 9 - Pharma Sector

Lupin, Sino Universal sign agreement to launch Tiotropium DPI in China

Tiotropium DPI, known for improving lung function and quality of life in patients with respiratory diseases, supports the aim to expand access to quality healthcare solutions in China

Largecap segment shines in Q4 amid broad sectoral divergence: Equirus Sec

Of the 270 companies analysed, largecaps saw a 6 per cent Y-o-Y earnings rise, midcaps gained 2 per cent, while smallcaps slumped 16 per cent.

Upcoming pharma park to position UP as bulk drug manufacturing hub

The Uttar Pradesh government is betting big on the upcoming pharma park in Lalitpur, which is expected to position the state alongside Gujarat and Andhra Pradesh as one of India's leading bulk drug manufacturing hubs. The project in the Bundelkhand region is expected to attract investments exceeding Rs 12,000 crore, according to the Uttar Pradesh State Industrial Development Authority (UPSIDA). Speaking to PTI, Mayur Maheshwari, Chief Executive Officer of UPSIDA, said, "The pharma park project in Lalitpur is one of the state government's landmark initiatives. It is entirely state-sponsored, aimed at achieving self-reliance in bulk drug and API manufacturing. The idea is for Uttar Pradesh to take the lead." Spread over 1,472 acres, the project has entered its first phase with 353 acres already under development. "We have secured environmental clearances and allotments for the first phase have begun," Maheshwari added. The project also lays thrust on having Zero Liquid Discharge (ZLD

Sun Pharma starts succession plan; Ganorkar succeeds Shanghvi as MD

Dilip Shanghvi to remain executive chairman while Ganorkar takes charge as MD from September 1 and Aalok Shanghvi is given additional charge of North America business

Sun Pharma appoints Kirti Ganorkar as MD after shareholders' approval

Gonarkar has been heading Sun Pharma's India business since 2019 and has previously held roles in marketing, new product introduction, among others, within the company

Why is Jubilant Pharmova share price buzzing in an overall weak market?

Jubilant Pharmova shares rose after its board approved the slump sale of its API business to wholly-owned subsidiary, Jubilant Biosys.

Bharat Biotech, GSK partner to develop vaccine for Shigella diarrhoea

Bharat Biotech on Thursday said it has partnered with GSK plc for the development of a vaccine for Shigellosis, a severe form of bacterial diarrhoea. The altSonflex1-2-3 vaccine candidate, developed by GSK and now advancing through a strategic collaboration with Bharat Biotech, represents one of the most advanced Shigella vaccine candidates globally, the company said in a statement. With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative Generalized Modules for Membrane Antigens (GMMA)-based platform, and robust early clinical results, it added. "With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries," Bharat Biotech Executive Chairman Krishna Ella said. As part of this agreement, Bharat Biotech will lead the further development of ...

Pharma body seeks rethink on entry curbs of MRs in govt hospitals

Indian Pharmaceutical Alliance warns that the DGHS ban on medical representatives may affect public health, slow innovation and result in pharma sector job losses

Marksans Pharma shares surge 5% after block trades; details here

Marksans Pharma shares rose 5 per cent after 10.27 million shares changed hands via multiple pre-market block trades

Advent to invest $175 million in animal health drugmaker Felix Pharma

The deal, which includes both primary and secondary transactions, positions Felix to accelerate its global ambitions as a differentiated player in the nascent but expanding companion animal generics

Indian pharma market grows 7.2% in May led by chronic therapies

Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches

AstraZeneca Pharma Q4 FY25 net profit jumps 48% to Rs 58.25 crore

Q4 net profit rises 48% to Rs 58.25 crore; revenue up 25.3% on strong growth across therapeutic areas, with oncology revenue up over 31% and record full-year sales

Here's why Natco Pharma share price is buzzing in trade on Thursday, May 29

Natco Pharma share price rose on the back of a healthy March quarter of financial year 2025 (Q4FY25) results.

Statsguru: Will most-favoured-nation pricing alter India-US pharma ties?

Nearly 35 per cent of India's pharma exports went to the US in FY25, breaching the $10 billion mark. Such exports have more than doubled since FY18

Pharma shares in focus; GSK, Jubilant, Eris, Gland, Torrent rally up to 8%

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as investors responded positively to strong Q4 results and favourable FY26 outlook

Sun Pharma Q4 preview: Analysts expect 18% jump in profit; check details

Sun Pharma Q4 results date: Sun Pharma is scheduled to announce its fourth quarter results on Thursday, May 22, 2025

Lupin to boost complex generics in US, EU; eyes chronic growth in India

Lupin plans to expand complex generics in developed markets and grow its chronic drug portfolio in India, with over 200 product launches and M&A on the radar

Trump's plans to cut drug prices in US may impact Indian pharma landscape

Trump's executive order, dated May 12, seeks to establish a mechanism through which American patients can buy their drugs directly from the manufacturers

Lupin Q4 results: Net profit zooms by 112% to ₹782 cr, revenue up 14%

The company's revenue from operations rose 14.2 per cent Y-o-Y to ₹5,671 crore, from ₹4,961 crore in Q4FY24

Cipla Q4FY25 results: Net profit zooms 30% to ₹1,221 cr, revenue up 9%

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent